New drug added to standard brain cancer treatment in early trial
NCT ID NCT06806228
Summary
This early-stage study is testing whether adding an experimental drug called S-Gboxin to standard brain cancer treatment is safe and effective. It involves 10 adults with aggressive brain tumors like glioblastoma who have already tried standard treatments. Researchers will monitor tumor size, side effects, and survival to see if the combination helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Kazakh Institute of Oncology and Radiology
Almaty, 490 078, Kazakhstan
-
National Cancer Institute
Kyiv, 33/43, Ukraine
-
Tbilisi Cancer Centre
Tbilisi, 0198, Georgia
Conditions
Explore the condition pages connected to this study.